RecentMedicalFindings.com
Summarizing relevant biomedical research!
bladder atrophy     Bookmark and Share
Search webpages of this site (RecentMedicalFindings):
Didn't find what you wanted? Try it at BioMedLib™ !
Search directly on the biomedical articles using BioMedLib™ search engine:



1. Biomedical articles (top 50; 2009 to 2014)
1. |||||..... 50%  O'Sullivan SS, Massey LA, Williams DR, Revesz T, Lees A, Holton J: Parkinson's disease with Onuf's nucleus involvement mimicking multiple system atrophy. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parkinson's disease with Onuf's nucleus involvement mimicking multiple system atrophy.
  • Urinary frequency, urgency and nocturia are common complaints in Parkinson's disease (PD).
  • The hypothesis most widely proposed to explain neurogenic bladder symptoms in PD is that cell loss in the substantia nigra may cause detrusor hyperactivity due to a loss in the D1 receptor-mediated tonic inhibition of the micturition reflex, although other causes including anti-parkinsonian medication cortical effects have been considered.1 We present the clinical and pathological findings of a patient with parkinsonism who presented with prominent dysautonomia and a poor response to dopaminergic medications and was considered to have possible multiple system atrophy parkinsonism (MSA-P).

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Neurol. 2000 Jul;48(1):97-101 [10894221.001]
  • [Cites] Mov Disord. 2005 Nov;20(11):1425-30 [16007638.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1645-8 [16291887.001]
  • [Cites] Mov Disord. 2006 Jun;21(6):737-45 [16570299.001]
  • [Cites] J Alzheimers Dis. 2006;9(3 Suppl):417-23 [16914880.001]
  • [Cites] Acta Neuropathol. 2007 Apr;113(4):421-9 [17294202.001]
  • [Cites] J Neuropathol Exp Neurol. 1979 Jul;38(4):353-68 [448397.001]
  • [Cites] J Neurol Sci. 1997 Mar 20;147(1):81-8 [9094064.001]
  • [Cites] J Anat. 1997 Aug;191 ( Pt 2):201-13 [9306197.001]
  • (PMID = 21686637.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Grant] United Kingdom / Parkinson's UK / / G-4062
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029569
  •  go-up   go-down


2. |||||..... 49%  Sakakibara R, Kishi M, Ogawa E, Tateno F, Uchiyama T, Yamamoto T, Yamanishi T: Bladder, bowel, and sexual dysfunction in Parkinson's disease. Parkinsons Dis; 2011;2011:924605
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder, bowel, and sexual dysfunction in Parkinson's disease.
  • Bladder dysfunction (urinary urgency/frequency), bowel dysfunction (constipation), and sexual dysfunction (erectile dysfunction) (also called "pelvic organ" dysfunctions) are common nonmotor disorders in Parkinson's disease (PD).
  • The brain pathology causing the bladder dysfunction (appearance of overactivity) involves an altered dopamine-basal ganglia circuit, which normally suppresses the micturition reflex.
  • The pathophysiology of the pelvic organ dysfunction in PD differs from that in multiple system atrophy; therefore, it might aid in differential diagnosis.
  • Anticholinergic agents are used to treat bladder dysfunction in PD, although these drugs should be used with caution particularly in elderly patients who have cognitive decline.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Res. 1999 Jan;39(1):11-9 [10051373.001]
  • [Cites] BJU Int. 1999 Mar;83 Suppl 2:1-6 [10210596.001]
  • [Cites] Neurourol Urodyn. 2000;19(1):101-9 [10602251.001]
  • [Cites] Urology. 2000 May;55(5A Suppl):51-7; discussion 59 [10767453.001]
  • [Cites] Intensive Care Med. 2000 Jul;26(7):901-7 [10990104.001]
  • [Cites] Trends Neurosci. 2000 Oct;23(10 Suppl):S2-7 [11052214.001]
  • [Cites] J Neurol Sci. 2001 Jun 15;187(1-2):55-9 [11440745.001]
  • [Cites] Horm Behav. 2002 Mar;41(2):170-7 [11855901.001]
  • [Cites] J Clin Gastroenterol. 2002 Mar;34(3):225-8 [11873100.001]
  • [Cites] J Gastrointest Surg. 2001 Jul-Aug;5(4):418-33 [11985985.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1016-22 [12195184.001]
  • [Cites] Asian J Androl. 2002 Dec;4(4):287-90 [12508130.001]
  • [Cites] J Comp Neurol. 2003 Apr 21;459(1):90-111 [12629668.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Jun;61(2B):359-63 [12894267.001]
  • [Cites] Clin Neuropharmacol. 1992 Oct;15(5):375-80 [1330307.001]
  • [Cites] Arch Gen Psychiatry. 1965 Jan;12:29-45 [14221689.001]
  • [Cites] Gastroenterology. 1951 Mar;17(3):367-74 [14823189.001]
  • [Cites] Neurogastroenterol Motil. 2004 Apr;16 Suppl 1:143-7 [15066021.001]
  • [Cites] Neuroscience. 2004;126(4):1075-82 [15207340.001]
  • [Cites] Drugs Aging. 2004;21(14):911-30 [15554750.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):124-9 [15654791.001]
  • [Cites] Dis Colon Rectum. 2000 Jul;43(7):940-3 [10910239.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G311-8 [10915639.001]
  • [Cites] Urology. 2000 Aug 1;56(2):250-4 [10925088.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Aug;279(2):R599-609 [10938251.001]
  • [Cites] J Urol. 2000 Nov;164(5):1640-3 [11025724.001]
  • [Cites] Spinal Cord. 2000 Oct;38(10):615-21 [11093323.001]
  • [Cites] Neurourol Urodyn. 2001;20(1):105-13 [11135387.001]
  • [Cites] J Clin Pharmacol. 2001 Jun;41(6):636-44 [11402632.001]
  • [Cites] Neurology. 2001 Aug 14;57(3):456-62 [11502913.001]
  • [Cites] Mov Disord. 2001 Nov;16(6):1176-7 [11748757.001]
  • [Cites] Exp Neurol. 2002 Jan;173(1):129-35 [11771945.001]
  • [Cites] Trends Neurosci. 2002 Jan;25(1):45-50 [11801338.001]
  • [Cites] Drugs Aging. 2004;21(11):687-709 [15323576.001]
  • [Cites] Neurourol Urodyn. 2004;23(7):689-96 [15382192.001]
  • [Cites] Mov Disord. 2005 Jun;20(6):680-6 [15719424.001]
  • [Cites] Clin Ther. 2005 Feb;27(2):144-53 [15811477.001]
  • [Cites] Clin Auton Res. 2005 Apr;15(2):76-82 [15834763.001]
  • [Cites] World J Gastroenterol. 2005 May 14;11(18):2691-6 [15884105.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 2):S5-10 [16458739.001]
  • [Cites] Br J Pharmacol. 2006 Feb;147 Suppl 2:S14-24 [16465178.001]
  • [Cites] Br J Pharmacol. 2006 Feb;147 Suppl 2:S25-40 [16465182.001]
  • [Cites] Intern Med. 2006;45(1):35-6 [16467605.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):994-8 [16469600.001]
  • [Cites] Urology. 2006 Mar;67(3):447-51 [16504269.001]
  • [Cites] Neurourol Urodyn. 2006;25(4):356-60 [16532465.001]
  • [Cites] Mol Psychiatry. 2006 Aug;11(8):782-6 [16619053.001]
  • [Cites] Int J Impot Res. 2006 Nov-Dec;18(6):550-8 [16625231.001]
  • [Cites] Br J Pharmacol. 2006 Jul;148(5):565-78 [16751797.001]
  • [Cites] Age Ageing. 2006 Sep;35(5):540-1 [16799178.001]
  • [Cites] Clin Auton Res. 2006 Aug;16(4):289-92 [16810464.001]
  • [Cites] J Urol. 2006 Aug;176(2):456-62 [16813864.001]
  • [Cites] J Urol. 2006 Aug;176(2):679-83 [16813919.001]
  • [Cites] BJU Int. 2006 Jul;98(1):125-31 [16831156.001]
  • [Cites] J Physiol Pharmacol. 2006 Jun;57(2):291-300 [16845232.001]
  • [Cites] Brain Res. 1990 Feb 26;510(1):104-7 [1691042.001]
  • [Cites] World J Gastroenterol. 2006 Aug 7;12(29):4609-13 [16937428.001]
  • [Cites] Rev Urol. 2002;4 Suppl 4:S7-S18 [16986023.001]
  • [Cites] Neuroscience. 2006 Nov 3;142(4):1273-80 [16996219.001]
  • [Cites] Brain. 2006 Dec;129(Pt 12):3366-75 [17077105.001]
  • [Cites] World J Gastroenterol. 2006 Nov 28;12(44):7069-74 [17131466.001]
  • [Cites] Mov Disord. 2007 Jan 15;22(2):220-5 [17133504.001]
  • [Cites] Mov Disord. 2007 Aug 15;22(11):1672-3 [17149723.001]
  • [Cites] Urology. 1976 Jan;7(1):24-8 [174263.001]
  • [Cites] Curr Top Med Chem. 2007;7(11):1137-44 [17584134.001]
  • [Cites] Klin Wochenschr. 1991 Dec 11;69(20):906-9 [1795497.001]
  • [Cites] Int J Impot Res. 2008 Jan-Feb;20(1):105-10 [18059502.001]
  • [Cites] J Urol. 2008 Mar;179(3):1066-71 [18206919.001]
  • [Cites] J Neural Transm. 2008;115(3):443-60 [18327532.001]
  • [Cites] Neurobiol Dis. 2009 Oct;36(1):96-102 [19595768.001]
  • [Cites] CNS Neurosci Ther. 2010 Jun;16(3):e92-123 [20557568.001]
  • [Cites] Adv Neurol. 1987;45:19-34 [2881444.001]
  • [Cites] Am J Psychiatry. 1978 Dec;135(12):1552-5 [717578.001]
  • [Cites] J Comp Neurol. 2000 Feb 21;417(4):399-414 [10701863.001]
  • [Cites] Brain. 2000 Apr;123 ( Pt 4):781-9 [10734009.001]
  • [Cites] Brain. 1995 Dec;118 ( Pt 6):1447-59 [8595476.001]
  • [Cites] Clin Neuropharmacol. 1995 Feb;18(1):76-8 [8665538.001]
  • [Cites] Neurourol Urodyn. 1997;16(2):111-5 [9042673.001]
  • [Cites] Eur Neurol. 1997;38 Suppl 2:2-7 [9387796.001]
  • [Cites] Mov Disord. 1997 Nov;12(6):923-7 [9399216.001]
  • [Cites] Mov Disord. 1997 Nov;12(6):946-51 [9399219.001]
  • [Cites] Mov Disord. 1997 Nov;12(6):952-7 [9399220.001]
  • [Cites] Brain Res Brain Res Rev. 1998 May;26(2-3):148-53 [9651511.001]
  • [Cites] Prog Neurobiol. 1998 Nov;56(4):433-506 [9775401.001]
  • [Cites] J Auton Nerv Syst. 1998 Dec 11;74(2-3):189-92 [9915636.001]
  • [Cites] Sheng Li Xue Bao. 1995 Jun;47(3):245-52 [7570109.001]
  • [Cites] Acta Neurol Scand. 1995 Jun;91(6):453-5 [7572039.001]
  • [Cites] Gut. 1976 Apr;17(4):306-12 [773793.001]
  • [Cites] Neurosci Lett. 1995 Jan 2;183(1-2):58-61 [7746488.001]
  • [Cites] Br J Surg. 1995 Feb;82(2):173-6 [7749679.001]
  • [Cites] World J Urol. 1995;13(1):30-3 [7773315.001]
  • [Cites] Mov Disord. 1995 Jan;10(1):66-70 [7885357.001]
  • [Cites] Mov Disord. 1995 Jan;10(1):81-4 [7885359.001]
  • [Cites] Dig Dis Sci. 1994 Nov;39(11):2364-7 [7956604.001]
  • [Cites] Mov Disord. 1993;8(1):83-6 [8093549.001]
  • [Cites] Acta Neuropathol. 1993;86(4):397-8 [8256591.001]
  • [Cites] Neurourol Urodyn. 1993;12(3):203-9 [8330043.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1070-1 [8402072.001]
  • [Cites] Mov Disord. 1993 Apr;8(2):151-7 [8474481.001]
  • [Cites] Ann Neurol. 1993 May;33(5):490-3 [8498826.001]
  • [Cites] Mov Disord. 1995 Sep;10(5):650-7 [8552119.001]
  • [Cites] Age Ageing. 1995 Nov;24(6):499-504 [8588540.001]
  • [Cites] Postgrad Med J. 1996 Mar;72(845):164-7 [8731708.001]
  • [Cites] Brain Res Brain Res Rev. 1995 Sep;21(2):162-84 [8866673.001]
  • [Cites] J Neurol Sci. 1996 Sep 15;141(1-2):105-10 [8880701.001]
  • [Cites] Mov Disord. 2002 Jan;17(1):223-5 [11835473.001]
  • [Cites] Neurourol Urodyn. 2002;21(2):167-78 [11857671.001]
  • [Cites] Mov Disord. 2002;17 Suppl 3:S63-8 [11948756.001]
  • [Cites] Parkinsonism Relat Disord. 2002 Mar;8(4):277-84 [12039423.001]
  • [Cites] Eur Urol. 2002 Apr;41(4):382-6 [12074807.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Nov;283(5):G1020-6 [12381514.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Dec;283(6):G1398-411 [12388212.001]
  • [Cites] Mov Disord. 2002 Nov;17(6):1371-4 [12465087.001]
  • [Cites] Jpn J Pharmacol. 2002 Dec;90(4):313-20 [12501007.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):259-63 [12591038.001]
  • [Cites] Physiol Res. 2003;52(1):1-30 [12625803.001]
  • [Cites] J Urol. 2003 Apr;169(4):1388-91 [12629368.001]
  • [Cites] J Urol. 2003 May;169(5):1878-84 [12686866.001]
  • [Cites] Mov Disord. 2003 May;18(5):573-8 [12722172.001]
  • [Cites] J Neurol. 2003 Feb;250 Suppl 1:I28-30 [12761632.001]
  • [Cites] Physiol Res. 2003;52(3):275-84 [12790758.001]
  • [Cites] J Pharmacol Sci. 2003 Jun;92(2):143-8 [12832842.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 2):S40-4; discussion S44-5 [12853772.001]
  • [Cites] Neuroscience. 2003;120(3):871-5 [12895527.001]
  • [Cites] Br J Pharmacol. 2003 Aug;139(8):1425-32 [12922929.001]
  • [Cites] Brain Res Bull. 1992 Aug;29(2):135-40 [1356067.001]
  • [Cites] Radiology. 1965 Jul;85:73-9 [14303073.001]
  • [Cites] Br J Urol. 1961 Dec;33:403-9 [14477379.001]
  • [Cites] Ann Neurol. 2004 Jan;55(1):118-20 [14705120.001]
  • [Cites] J Sex Marital Ther. 2004 Mar-Apr;30(2):95-105 [14742099.001]
  • [Cites] Parkinsonism Relat Disord. 2004 Mar;10(3):181-7 [15036175.001]
  • [Cites] Brain Res. 1992 May 15;580(1-2):92-9 [1504821.001]
  • [Cites] Neurourol Urodyn. 2004;23(3):265-72 [15098225.001]
  • [Cites] J Am Geriatr Soc. 2005 Dec;53(12):2195-201 [16398909.001]
  • [Cites] J Urol. 2006 Jan;175(1):202-6; discussion 206-7 [16406911.001]
  • [Cites] Int J Urol. 2006 Jan;13(1):29-35 [16448429.001]
  • [Cites] Clin Gastroenterol. 1986 Oct;15(4):937-65 [3536215.001]
  • [Cites] J Am Geriatr Soc. 1987 Jul;35(7):683-4 [3584772.001]
  • [Cites] J Pharmacol Exp Ther. 1987 Aug;242(2):548-51 [3612550.001]
  • [Cites] J Urol. 1987 Oct;138(4):836-8 [3656541.001]
  • [Cites] Clin Neuropharmacol. 1986;9(5):440-7 [3768866.001]
  • [Cites] Dig Dis Sci. 1985 May;30(5):419-25 [3987475.001]
  • [Cites] Int Urol Nephrol. 1985;17(1):35-41 [3997405.001]
  • [Cites] Gastroenterology. 1985 Dec;89(6):1411-4 [4054533.001]
  • [Cites] Eur J Clin Pharmacol. 1985;29(3):307-10 [4076326.001]
  • [Cites] Acta Neurol Scand. 1985 Nov;72(5):506-11 [4082917.001]
  • [Cites] Br J Urol. 1985 Dec;57(6):652-6 [4084724.001]
  • [Cites] Gastroenterology. 1984 Oct;87(4):848-56 [6088351.001]
  • [Cites] Br J Clin Pharmacol. 1984 Dec;18(6):959-62 [6529536.001]
  • [Cites] JAMA. 1983 Mar 4;249(9):1148 [6823069.001]
  • [Cites] J Urol. 1983 Jan;129(1):80-3 [6827689.001]
  • [Cites] Gastroenterology. 1983 Jul;85(1):105-13 [6852445.001]
  • [Cites] Mov Disord. 1995 May;10(3):337-40 [7651453.001]
  • [Cites] Am J Gastroenterol. 1994 Jan;89(1):15-25 [8273792.001]
  • [Cites] J Neurol. 1991 Feb;238(1):19-22 [1851513.001]
  • [Cites] Gut. 1991 Aug;32(8):941-4 [1885077.001]
  • [Cites] Urol Int. 2008;81(3):335-9 [18931554.001]
  • [Cites] Dig Dis Sci. 1990 Mar;35(3):327-32 [1968372.001]
  • [Cites] Acta Neuropathol. 1990;79(6):581-3 [1972853.001]
  • [Cites] Behav Brain Res. 2010 Jan 20;206(2):286-92 [19782104.001]
  • [Cites] J Sex Med. 2010 Feb;7(2 Pt 2):858-72 [19929916.001]
  • [Cites] J Sex Med. 2010 Jun;7(6):2056-67 [20345736.001]
  • [Cites] Mov Disord. 1991;6(2):151-6 [2057006.001]
  • [Cites] J Epidemiol Community Health. 1990 Sep;44(3):246-8 [2148771.001]
  • [Cites] Neurology. 1990 Sep;40(9):1347-9 [2392215.001]
  • [Cites] Arch Int Physiol Biochim. 1985 Jun;93(2):93-100 [2412517.001]
  • [Cites] Arch Neurol. 1989 Oct;46(10):1061-4 [2803065.001]
  • [Cites] Neurology. 1987 Jul;37(7):1253-5 [3037441.001]
  • [Cites] Neurosci Lett. 1986 Mar 28;65(1):79-83 [3486388.001]
  • [Cites] Ann Neurol. 1978 Feb;3(2):129-33 [350130.001]
  • [Cites] Mov Disord. 2005 Nov;20(11):1425-30 [16007638.001]
  • [Cites] Gut. 2005 Aug;54(8):1107-13 [16009682.001]
  • [Cites] Physiol Behav. 2005 Oct 15;86(3):356-68 [16135375.001]
  • [Cites] Neurogastroenterol Motil. 2005 Oct;17(5):637-42 [16185301.001]
  • [Cites] Neurology. 2005 Dec 27;65(12):1863-72 [16237129.001]
  • [Cites] J Comp Neurol. 2005 Dec 5;493(1):21-6 [16255005.001]
  • [Cites] J Comp Neurol. 2005 Dec 5;493(1):27-32 [16255006.001]
  • [Cites] Neurogastroenterol Motil. 2006 Feb;18(2):91-103 [16420287.001]
  • [Cites] J Neurosci. 2006 Mar 8;26(10):2798-807 [16525059.001]
  • [Cites] Neurology. 2006 Jul 11;67(1):125-30 [16832090.001]
  • [Cites] Brain. 2008 Jan;131(Pt 1):132-45 [17977862.001]
  • [Cites] J Urol. 2008 Oct;180(4):1241-8 [18707740.001]
  • [Cites] Pharmacol Res. 1996 Apr-May;33(4-5):217-26 [8938012.001]
  • [Cites] Mov Disord. 1997 May;12(3):423-5 [9159740.001]
  • [Cites] Clin Auton Res. 1997 Jun;7(3):163-5 [9232362.001]
  • [Cites] Br J Urol. 1997 Jul;80(1):100-4 [9240187.001]
  • [Cites] Neurosci Lett. 1997 Sep 19;233(2-3):109-12 [9350844.001]
  • [Cites] Adv Exp Med Biol. 1997;427:211-9 [9361846.001]
  • [Cites] Mov Disord. 1997 Sep;12(5):764-6 [9380063.001]
  • [Cites] Br J Urol. 1997 Dec;80(6):940-5 [9439415.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Jul;286(1):228-33 [9655864.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Aug;158(2):458-64 [9700121.001]
  • [Cites] Wien Klin Wochenschr. 1998 Aug 21;110(15):535-7 [9782572.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 2):R2049-55 [9843896.001]
  • [Cites] Neuroscience. 1998 Sep;86(2):353-87 [9881853.001]
  • [Cites] Eur Neurol. 1992;32(3):134-40 [1592069.001]
  • [Cites] Sleep Med Rev. 2005 Aug;9(4):311-29 [15994100.001]
  • [Cites] Parkinsonism Relat Disord. 2005 Dec;11(8):509-12 [15994112.001]
  • [Cites] Prog Neurobiol. 2005 May;76(1):1-21 [16043278.001]
  • [Cites] Parkinsonism Relat Disord. 2005 Sep;11(6):381-6 [16109498.001]
  • [Cites] Neuroscience. 2005;135(1):299-303 [16111828.001]
  • [Cites] Mov Disord. 2006 Jan;21(1):115-6 [16142776.001]
  • [Cites] Prog Brain Res. 2006;152:335-43 [16198711.001]
  • [Cites] Prog Brain Res. 2006;152:359-72 [16198713.001]
  • [Cites] Eur J Neurol. 2005 Nov;12(11):842-50 [16241972.001]
  • [Cites] Parkinsonism Relat Disord. 2005 Dec;11(8):499-502 [16263322.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Nov 15;22(10):997-1003 [16268975.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1373-7 [16287461.001]
  • [Cites] Jpn J Psychiatry Neurol. 1992 Mar;46(1):181-6 [1635308.001]
  • [Cites] Br J Urol. 1992 Jul;70(1):100-2 [1638364.001]
  • (PMID = 21918729.001).
  • [ISSN] 2042-0080
  • [Journal-full-title] Parkinson's disease
  • [ISO-abbreviation] Parkinsons Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3171780
  •  go-up   go-down


3. |||||..... 49%  Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Köllensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, del Sorbo F, Tolosa E, Cardozo A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner WG, Tison F, Poewe W, European Multiple System Atrophy Study Group: The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol; 2013 Mar;12(3):264-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history of multiple system atrophy: a prospective European cohort study.
  • BACKGROUND: Multiple system atrophy (MSA) is a fatal and still poorly understood degenerative movement disorder that is characterised by autonomic failure, cerebellar ataxia, and parkinsonism in various combinations.
  • METHODS: Patients with a clinical diagnosis of MSA were recruited and followed up clinically for 2 years.
  • The parkinsonian variant of MSA (hazard ratio [HR] 2·08, 95% CI 1·09-3·97; p=0·026) and incomplete bladder emptying (HR 2·10, 1·02-4·30; p=0·044) predicted shorter survival.
  • [MeSH-major] Disease Progression. Multiple System Atrophy
  • [MeSH-minor] Aged. Autonomic Nervous System Diseases / diagnosis. Autonomic Nervous System Diseases / mortality. Autonomic Nervous System Diseases / physiopathology. Cerebellar Ataxia / diagnosis. Cerebellar Ataxia / mortality. Cerebellar Ataxia / physiopathology. Cohort Studies. Europe. Humans. Male. Middle Aged. Parkinson Disease / diagnosis. Parkinson Disease / mortality. Parkinson Disease / physiopathology. Phenotype. Prospective Studies. Severity of Illness Index


Advertisement
4. |||||||||. 37732%  Cooper IF, Siadaty MS: 'Pathologic Functions' associated with 'Bladder Atrophy': Top Publications. BioMedLib Review; PathologicFunction;BladderAtrophy:706817524. ISSN: 2331-5717. 2014/8/1
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Pathologic Functions' associated with 'Bladder Atrophy': Top Publications.
  • [Transliterated title]
  • Background: There are articles published each month which present 'Pathologic Function' for 'bladder atrophy'.
  • Finding such articles is important for researchers, clinicians, and patients.
  • However these articles are spread across thousands of journals, and there are many types of 'Pathologic Function'.
  • This makes searching and locating the relevant publications a challenge.
  • We have used BioMedLib's semantic search technology to address the issue, and gathered all the pertinent publications in this review article.
  • Methods: We categorized the publications we found into two groups.
  • We used the strength of textual-association to separate the groups.
  • In group one there are publications with the strongest evidence of association. We focused finding the most relevant publications pertinent to our goal, rather than combining them into a conclusion section. Such textual synthesis will be the focus of our next project.
  • Results: Group one includes 15 publications, and group two 647 publications.
  • Here are the top 9.
  • Koizumi S et al: [Adenocarcinoma occurring 37 years after augmentation ileocystoplasty for tuberculous bladder atrophy: report of a case].
  • Nakata W et al: [A rare case of transitional cell carcinoma of the ileum segment arising 43 years after ureteroileocystoplasty due to tuberculous bladder atrophy].
  • Okoshi M et al: [Cystectasia for bladder atrophy in patients with a single kidney].
  • CIBERT J et al: [Entero-cystoplasty in post-tuberculous bladder atrophy].
  • Murayama K et al: [Clinical application of thyrotropin-releasing hormone to neurogenic bladder caused by olivo-ponto-cerebellar atrophy].
  • Boudes M et al: Bladder dysfunction in a transgenic mouse model of multiple system atrophy.
  • Peterson T et al: Simultaneous arterial and urinary bladder pressure recordings in multiple system atrophy and in spinal disorders with detrusor hyperreflexia.
  • Cremers CW et al: Juvenile diabetes mellitus, optic atrophy, hearing loss, diabetes insipidus, atonia of the urinary tract and bladder, and other abnormalities (Wolfram syndrome). A review of 88 cases from the literature with personal observations on 3 new patients.
  • Chaudhuri KR: Management of bladder dysfunction in patients with multiple-system atrophy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 706817524.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


5. |||||||||. 1696%  Pagano D, Cintorino D, Li Petri S, di Francesco F, Ricotta C, Argento J, Echeverri GJ, Bertani T, Riva S, Gridelli BG, Spada M: Laparoscopic approach for an intra-abdominal kidney allograft nephrectomy after pediatric transplantation: a case report. Transplant Proc; 2012 Sep;44(7):2036-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 15-year-old girl underwent transplantation with a cadaveric donor kidney due to congenital pyelonephritis, vesicoureteral reflux, and secondary bladder atrophy.
  • After recurrent urinary tract infections, the patient was reintroduced to hemodialysis in 2010.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 Elsevier Inc. All rights reserved.
  • (PMID = 22974901.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. |||||..... 46%  Karthik TS, Prasad NR, Rani PR, Maheshwari R, Reddy PA, Chakradhar BV, Menon B: A rare case of short stature: Say Meyer syndrome. Indian J Endocrinol Metab; 2013 Oct;17(Suppl 1):S130-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He had global developmental delay and there was a lack of bowel and bladder control.
  • Magnetic resonance imaging (MRI) brain revealed mild diffuse frontotemporal atrophy with multiple irregular gliotic areas in bilateral frontal lobes.
  • Characteristic MRI brain findings include diffuse frontotemporal atrophy with multiple gliotic areas in frontal lobes.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24251132.001).
  • [ISSN] 2230-8210
  • [Journal-full-title] Indian journal of endocrinology and metabolism
  • [ISO-abbreviation] Indian J Endocrinol Metab
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3830278
  • [Keywords] NOTNLM ; Craniosynostosis / Say Meyer syndrome / frontotemporal atrophy / multiple gliotic areas / short stature
  •  go-up   go-down


7. |||||..... 47%  Rambau PF, Chandika A, Chalya PL, Jackson K: Scrotal Swelling and Testicular Atrophy due to Schistosomiasis in a 9-Year-Old Boy: A Case Report. Case Rep Infect Dis; 2011;2011:787961
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scrotal Swelling and Testicular Atrophy due to Schistosomiasis in a 9-Year-Old Boy: A Case Report.
  • Schistosomiasis is a communicable disease which commonly involves urinary bladder causing hematuria, or large bowel causing bloody stool.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22567478.001).
  • [ISSN] 2090-6633
  • [Journal-full-title] Case reports in infectious diseases
  • [ISO-abbreviation] Case Rep Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC3336235
  •  go-up   go-down


8. |||||..... 46%  Naderian G, Ashtari F, Nouri-Mahdavi K, Sajjadi V: A case of wolfram syndrome. J Ophthalmic Vis Res; 2010 Jan;5(1):53-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report a case of Wolfram syndrome characterized by early onset diabetes mellitus and progressive optic atrophy.
  • Bilateral optic atrophy was evident on fundus examination.
  • The patient also had diabetes insipidus, neurosensory deafness, neurogenic bladder, polyuria and extra-residual voiding indicating atony of the urinary tract, combined with delayed sexual maturity.
  • Ophthalmological examination may disclose optic atrophy; urologic examinations are vital in such patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Ophthalmol. 1977 Mar-Apr;14(2):106-8 [874711.001]
  • [Cites] Acta Paediatr Scand Suppl. 1977;(264):1-16 [270276.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):143-8 [9771706.001]
  • [Cites] Nephrol Dial Transplant. 2003 Jan;18(1):206-8 [12480986.001]
  • [Cites] Lancet. 1995 Dec 2;346(8988):1458-63 [7490992.001]
  • [Cites] J Inherit Metab Dis. 1992;15(3):315-9 [1383603.001]
  • [Cites] J Med Genet. 1977 Jun;14(3):190-3 [881709.001]
  • [Cites] J Med Genet. 1997 Oct;34(10):838-41 [9350817.001]
  • [Cites] Hum Mol Genet. 1998 Dec;7(13):2021-8 [9817917.001]
  • [Cites] Diabetologia. 2008 Mar;51(3):458-63 [18040659.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1950 Jun 7;25(12):320-6 [15424239.001]
  • [Cites] Ann Ophthalmol (Skokie). 2007 Spring;39(1):53-5 [17914206.001]
  • [Cites] J Pediatr. 1976 Oct;89(4):565-70 [956998.001]
  • [Cites] Klin Wochenschr. 1982 May 3;60(9):471-5 [7045512.001]
  • [Cites] J Urol. 1999 Feb;161(2):616-7 [9915470.001]
  • [Cites] Histochem Cell Biol. 2003 Mar;119(3):247-56 [12649740.001]
  • [Cites] Q J Med. 1976 Jul;45(179):505-20 [948548.001]
  • [Cites] Diabetes Care. 1995 Dec;18(12):1566-70 [8722052.001]
  • (PMID = 22737327.001).
  • [ISSN] 2008-2010
  • [Journal-full-title] Journal of ophthalmic & vision research
  • [ISO-abbreviation] J Ophthalmic Vis Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3380670
  • [Keywords] NOTNLM ; Deafness / Diabetes Insipidus / Diabetes Mellitus / Optic Atrophy
  •  go-up   go-down


9. |||||||||. 1689%  Watanabe T, Masago T, Miyagawa I: Apoptotic action of botulinum toxin on detrusor muscle in rats. Urol Int; 2010;84(3):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The bladder wall and prostate in adult male Sprague-Dawley rats were injected with BTX-A (10 U at each site).
  • RESULTS: Although bladder weight was significantly increased in the BTX-A group compared to controls, no significant changes in prostate weight were identified.
  • CONCLUSIONS: The lack of significant changes in cellular dynamics of the detrusor muscle in the current study suggests that BTX-A injection into detrusor muscle for overactive bladder may not induce bladder atrophy.

  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20389167.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


10. |||||..... 52%  Boudes M, Uvin P, Pinto S, Voets T, Fowler CJ, Wenning GK, De Ridder D, Stefanova N: Bladder dysfunction in a transgenic mouse model of multiple system atrophy. Mov Disord; 2013 Mar;28(3):347-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder dysfunction in a transgenic mouse model of multiple system atrophy.
  • Multiple system atrophy (MSA) is an adult-onset neurodegenerative disorder presenting with motor impairment and autonomic dysfunction.
  • To date, bladder function and structure have never been investigated in MSA models.
  • We aimed to test bladder function in a transgenic MSA mouse featuring oligodendroglial α-synucleinopathy and define its applicability as a preclinical model to study urological failure in MSA.
  • Bladder morphology and neuropathology of the lumbosacral intermediolateral column and the pontine micturition center (PMC) were analyzed in young and aged mice.
  • Urodynamic analysis revealed a less efficient and unstable bladder in MSA mice with increased voiding contraction amplitude, higher frequency of nonvoiding contractions, and increased postvoid residual volume.
  • MSA mice bladder walls showed early detrusor hypertrophy and age-related urothelium hypertrophy.
  • [MeSH-major] Multiple System Atrophy / complications. Urinary Bladder Diseases / etiology
  • [MeSH-minor] Acetylcholine / pharmacology. Age Factors. Animals. Brain / pathology. Disease Models, Animal. Disease Progression. Diuresis / drug effects. Diuresis / physiology. Female. Gene Expression Regulation / genetics. Humans. Image Cytometry. Male. Mice. Mice, Inbred C57BL. Mice, Transgenic. Myelin Proteolipid Protein / genetics. Urinary Bladder / drug effects. Urinary Bladder / metabolism. Urinary Bladder / physiopathology. Uterine Contraction / drug effects. Uterine Contraction / genetics. alpha-Synuclein / genetics

  • Genetic Alliance. consumer health - Multiple system atrophy.
  • Genetics Home Reference. consumer health - SNCA Gene.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 Movement Disorder Society.
  • (PMID = 23426727.001).
  • [ISSN] 1531-8257
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Publication-type] In Vitro; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myelin Proteolipid Protein; 0 / Plp1 protein, mouse; 0 / alpha-Synuclein; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


11. |||||..... 51%  Hillard T: The postmenopausal bladder. Menopause Int; 2010 Jun;16(2):74-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The postmenopausal bladder.
  • The bladder and its surrounding structures are rich in estrogen receptors and there are demonstrable physiological and anatomical changes that occur around and immediately after the menopause.
  • The prevalence of many bladder symptoms, such as frequency, urgency and incontinence, does seem to increase around the menopause, but there is continuing debate over whether these effects are due to ageing, menopause or a combination of the two.
  • The impact of the menopause varies with individual symptoms; stress urinary incontinence being associated more with estrogen deficiency than urge incontinence which seems to be more age-related.
  • Based on these effects, it could be anticipated that estrogen replacement would have a positive effect on bladder symptoms.
  • It seems that topical estrogens do have some positive effects, particularly on symptoms of urgency, frequency and urge incontinence, the prevention of urogenital atrophy and in the prevention of recurrent urinary tract infections.
  • The possible explanations for this apparent contradiction are explored, but based on current evidence, it would appear preferable to use vaginal estrogens rather than systemic as part of the management of menopause-related bladder problems.
  • [MeSH-major] Estrogen Replacement Therapy. Postmenopause / physiology. Urinary Bladder / physiopathology. Urinary Incontinence / etiology. Urinary Incontinence / physiopathology
  • [MeSH-minor] Administration, Intravaginal. Age Factors. Female. Humans. Receptors, Estrogen / physiology. Receptors, Progesterone / physiology. Urinary Tract Infections / prevention & control

  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20729499.001).
  • [ISSN] 1754-0461
  • [Journal-full-title] Menopause international
  • [ISO-abbreviation] Menopause Int
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


12. |||||..... 51%  Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A: Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol; 2009 Oct;182(4):1453-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
  • PURPOSE: Urinary disturbances are common in patients with Parkinson's disease and multiple system atrophy.
  • We investigated the effectiveness and safety of botulinum toxin type A injected into the detrusor muscle in patients with Parkinson's disease and multiple system atrophy who had refractory overactive bladder symptoms and detrusor overactivity.
  • Four patients with Parkinson's disease and 2 with multiple system atrophy were enrolled in the study.
  • Outcome measures were clinical assessment (a voiding diary including daytime and nighttime urinary frequency, and episodes of urgency and urge urinary incontinence), urodynamic assessment (including first volume and maximum pressure of uninhibited detrusor contractions, and maximum cystometric capacity) and pressure flow studies.
  • RESULTS: One and 3 months after botulinum toxin type A injection all patients reported that daytime and nighttime urinary frequency had decreased and quality of life scores improved.
  • No patients had further episodes of urgency and urge urinary incontinence during the 5-month followup.
  • Urodynamics showed improvement in all urinary function variables tested.
  • In all patients post-void urinary residual volume increased and intermittent catheterization was required only in those with multiple system atrophy.
  • CONCLUSIONS: The new beneficial effect that we report in a small study sample encourages larger trials to confirm botulinum toxin type A injection into the detrusor muscle as an effective and safe treatment for refractory overactive bladder symptoms and detrusor overactivity related to Parkinson's disease and multiple system atrophy.
  • [MeSH-major] Botulinum Toxins, Type A / therapeutic use. Multiple System Atrophy / complications. Neuromuscular Agents / therapeutic use. Parkinson Disease / complications. Urinary Bladder, Overactive / drug therapy. Urinary Bladder, Overactive / etiology


13. |||||..... 51%  Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Klockgether T, Yekhlef F, Tison F, Daniels C, Deuschl G, Coelho M, Sampaio C, Bozi M, Quinn N, Schrag A, Mathias CJ, Fowler C, Nilsson CF, Widner H, Schimke N, Oertel W, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Colosimo C, Meco G, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Rascol O, Kamm C, Gasser T, Siebert U, Poewe W, Wenning GK, EMSA-SG: Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord; 2010 Nov 15;25(15):2604-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry.
  • Multiple system atrophy (MSA) is a Parkinson's Disease (PD)-like α-synucleinopathy clinically characterized by dysautonomia, parkinsonism, cerebellar ataxia, and pyramidal signs in any combination.
  • In 19 European MSA Study Group centres all consecutive patients with a clinical diagnosis of MSA were recruited from 2001 to 2005.
  • Symptomatic dysautonomia was present in almost all patients, and urinary dysfunction (83%) more common than symptomatic orthostatic hypotension (75%).
  • Less than a third of patients with documented orthostatic hypotension or neurogenic bladder disturbance were receiving treatment.
  • [MeSH-major] Multiple System Atrophy / diagnosis. Multiple System Atrophy / therapy. Registries
  • [MeSH-minor] Age of Onset. Antiparkinson Agents / therapeutic use. Cerebellar Ataxia / diagnosis. Cerebellar Ataxia / physiopathology. Europe. Female. Humans. Hypotension, Orthostatic / diagnosis. Hypotension, Orthostatic / physiopathology. Levodopa / therapeutic use. Male. Middle Aged. Parkinsonian Disorders / diagnosis. Parkinsonian Disorders / drug therapy. Parkinsonian Disorders / physiopathology. Shy-Drager Syndrome / diagnosis. Shy-Drager Syndrome / physiopathology

  • Genetic Alliance. consumer health - Multiple system atrophy.
  • Genetics Home Reference. consumer health - multiple system atrophy.
  • HSDB. structure - LEVODOPA.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Movement Disorder Society.
  • (PMID = 20922810.001).
  • [ISSN] 1531-8257
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 46627O600J / Levodopa
  •  go-up   go-down


14. |||||..... 51%  Bloch F, Pichon B, Bonnet AM, Pichon J, Vidailhet M, Roze E, Perrigot M: Urodynamic analysis in multiple system atrophy: characterisation of detrusor-sphincter dyssynergia. J Neurol; 2010 Dec;257(12):1986-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urodynamic analysis in multiple system atrophy: characterisation of detrusor-sphincter dyssynergia.
  • In multiple system atrophy (MSA), parkinsonism and a cerebellar syndrome are associated with autonomic dysfunction.
  • Both bladder neck dysfunction and external sphincter denervation have been implicated in detrusor-sphincter dyssynergia.
  • Pressure assessment at several levels of the urethra is needed to unravel the mechanisms of bladder-urethra dysfunction.
  • Here, we evaluated the use of multiple sensor pressure transducers to assess bladder-sphincter function in 52 patients with MSA in comparison to patients with Parkinson's disease (PD) who were matched for age and severity in the "off" condition.
  • Urinary dysfunction appeared significantly earlier in MSA (<2 years) than in PD (>5 years).
  • Detrusor-urethral dyssynergia in MSA patients was always better characterized by multiple sensor pressure transducer measurement of bladder and urethral pressure than by a single global measurement.
  • This new approach may prove useful for differential diagnosis of parkinsonian syndromes, and especially MSA.
  • [MeSH-major] Multiple System Atrophy / physiopathology. Urinary Bladder / physiopathology. Urinary Bladder, Neurogenic / diagnosis. Urinary Bladder, Neurogenic / physiopathology. Urination / physiology


15. |||||..... 50%  Kokubun S, Ozawa H, Aizawa T, Ly NM, Tanaka Y: Spine-shortening osteotomy for patients with tethered cord syndrome caused by lipomyelomeningocele. J Neurosurg Spine; 2011 Jul;15(1):21-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Preoperatively, all patients displayed severe neurological deficits such as motor disturbance, muscle atrophy, and bladder dysfunction.

  • Genetic Alliance. consumer health - Lipomyelomeningocele.
  • MedlinePlus Health Information. consumer health - Neural Tube Defects.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg Spine. 2011 Jul;15(1):19-20; author reply p 20 [21495811.001]
  • (PMID = 21495816.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Lipomyelomeningocele
  •  go-up   go-down


16. |||||..... 50%  Harik LR, O'Toole KM: Nonneoplastic lesions of the prostate and bladder. Arch Pathol Lab Med; 2012 Jul;136(7):721-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonneoplastic lesions of the prostate and bladder.
  • CONTEXT: Specimens from the prostate and bladder are commonly encountered by the general surgical pathologist.
  • Emphasis is usually placed on neoplasms of the bladder and prostate, particularly if malignant, owing to their therapeutic consequences.
  • A good command of benign lesions occurring in the bladder and prostate, and knowledge of their preneoplastic potential will help pathologists confidently diagnose malignancy versus its benign mimickers and guide the urologists in choosing the appropriate therapy and follow-up for the patient.
  • CONCLUSIONS: A wide variety of benign entities are present in the prostate and bladder.
  • Benign lesions in the prostate can be age related, such as prostatic atrophy and benign prostatic hyperplasia; transition zone associated, such as basal cell hyperplasia, adenosis, and sclerosing adenosis; or prostatic urethra associated.
  • Benign lesions of the bladder encompass a wide variety of reactive changes that can occur in the urothelium, as well as hyperplastic lesions or reactive proliferations that could be misdiagnosed as malignant.
  • The bladder responds to chronic irritation through several reactive/metaplastic lesions such as cystitis cystica/glandularis, keratinizing squamous metaplasia, or nephrogenic metaplasia.
  • [MeSH-major] Prostate / pathology. Prostatitis / pathology. Urinary Bladder / pathology. Urinary Bladder Diseases / pathology
  • [MeSH-minor] Atrophy. Humans. Male

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22742546.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


17. |||||||||. 817%  Cooper IF, Siadaty MS: 'Pathologic Functions' associated with 'Anastomosis Of Bladder With Isolated Segment Of Ileum': Top Publications. BioMedLib Review; PathologicFunction;AnastomosisOfBladder:706882262. ISSN: 2331-5717. 2014/1/2
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Pathologic Functions' associated with 'Anastomosis Of Bladder With Isolated Segment Of Ileum': Top Publications.
  • [Transliterated title]
  • Background: There are articles published each month which present 'Pathologic Function' for 'anastomosis of bladder with isolated segment of ileum'.
  • Finding such articles is important for researchers, clinicians, and patients.
  • However these articles are spread across thousands of journals, and there are many types of 'Pathologic Function'.
  • This makes searching and locating the relevant publications a challenge.
  • We have used BioMedLib's semantic search technology to address the issue, and gathered all the pertinent publications in this review article.
  • Methods: We categorized the publications we found into two groups.
  • We used the strength of textual-association to separate the groups.
  • In group one there are publications with the strongest evidence of association. We focused finding the most relevant publications pertinent to our goal, rather than combining them into a conclusion section. Such textual synthesis will be the focus of our next project.
  • Results: Group one includes 23 publications, and group two 350 publications.
  • Here are the top 10.
  • Armah HB et al: Tubular adenoma with high-grade dysplasia in the ileal segment 34 years after augmentation ileocystoplasty: report of a first case.
  • Kishino T et al: [Assessment of surgical invasiveness of augmentation ileocystoplasty applying the systemic inflammatory response syndrome score in patients with spina bifida].
  • Desgrandchamps F et al: Spontaneous rupture of orthotopic detubularized ileal bladder replacement: report of 5 cases.
  • Mitsui T et al: Preoperative renal scar as a risk factor of postoperative metabolic acidosis following ileocystoplasty in patients with neurogenic bladder.
  • Kawamura S et al: [A case of replacement ileocystoplasty for contracted bladder].
  • Beiko DT et al: Cerebrospinal fluid pseudocyst: a postoperative complication of augmentation ileocystoplasty in myelodysplastic children.
  • Koizumi S et al: [Adenocarcinoma occurring 37 years after augmentation ileocystoplasty for tuberculous bladder atrophy: report of a case].
  • Razmaria AA et al: Does robot-assisted laparoscopic ileocystoplasty (RALI) reduce peritoneal adhesions compared with open surgery?.
  • Robles MW et al: Adenocarcinoma and dysplasia in an ileal neobladder after ileocystoplasty for interstitial cystitis.
  • HABA T et al: [Ileocystoplasty for tuberculous contracted bladder].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 706882262.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


18. |||||..... 50%  Kohli J, Brandt N: Multiple-system atrophy and medications: how to minimize the risk of falling. Consult Pharm; 2011 Mar;26(3):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple-system atrophy and medications: how to minimize the risk of falling.
  • Following a chart review and interview with the resident, the consultant pharmacist found that her past medical history consists of coronary artery disease, atrial fibrillation, congestive heart failure, hypertension, dyslipidemia, osteoporosis, gastroesophageal reflux disease, glaucoma, mild dementia, overactive bladder, and Parkinson's disease (PD).
  • During the review, the consultant pharmacist found a recent neurology note that concluded the resident may have multiple-system atrophy (MSA) and her therapy for PD may not be beneficial.
  • [MeSH-major] Accidental Falls / prevention & control. Autonomic Nervous System Diseases / etiology. Hypotension, Orthostatic / etiology. Multiple System Atrophy / complications


19. |||||..... 50%  Yamamoto T, Sakakibara R, Uchiyama T, Liu Z, Ito T, Awa Y, Yamanishi T, Hattori T: Questionnaire-based assessment of pelvic organ dysfunction in multiple system atrophy. Mov Disord; 2009 May 15;24(7):972-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Questionnaire-based assessment of pelvic organ dysfunction in multiple system atrophy.
  • Multiple system atrophy (MSA) is a neurodegenerative disease characterized clinically by any combination of autonomic, cerebellar, and extrapyramidal symptoms.
  • Autonomic symptoms are usually severe, and urinary symptoms are one of the cardinal features of MSA.
  • The questionnaire had sections focusing on the bladder, bowel, and sexual function.
  • When compared with the control group, the prevalence of pelvic organ dysfunction in the MSA group was significantly higher for urinary storage and voiding dysfunction, bowel dysfunction, and sexual dysfunction.
  • QOL in the MSA group was therefore significantly impaired because of urinary dysfunction (70%, 76%), bowel dysfunction (40% of the men), and sexual dysfunction (26%, 45%).
  • [MeSH-major] Constipation / etiology. Multiple System Atrophy / complications. Pelvis / physiopathology. Questionnaires. Urinary Bladder Diseases / etiology


20. |||||..... 50%  Deguchi K, Ikeda K, Goto R, Tsukaguchi M, Urai Y, Kurokohchi K, Touge T, Mori N, Masaki T: The close relationship between life-threatening breathing disorders and urine storage dysfunction in multiple system atrophy. J Neurol; 2010 Aug;257(8):1287-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The close relationship between life-threatening breathing disorders and urine storage dysfunction in multiple system atrophy.
  • Survival of multiple system atrophy (MSA) depends on whether a variety of sleep-related breathing problems as well as autonomic failure (AF) occur.
  • In 15 patients with MSA, we performed autonomic function tests composed of postural challenges and administered a questionnaire on bladder condition, as well as polysomnography and laryngoscopy during wakefulness and under anesthesia.
  • Polysomnographic variables such as the apnea-hypopnea index (AHI) and oxygen saturation (SpO(2)) and the findings of laryngoscopy were compared with the degree of cardiac and urinary autonomic dysfunction.
  • [MeSH-major] Multiple System Atrophy / complications. Respiratory Insufficiency / diagnosis. Shy-Drager Syndrome / diagnosis. Shy-Drager Syndrome / physiopathology. Urinary Bladder, Neurogenic / physiopathology


21. |||||..... 50%  Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T: Pathophysiology of bladder dysfunction in Parkinson's disease. Neurobiol Dis; 2012 Jun;46(3):565-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathophysiology of bladder dysfunction in Parkinson's disease.
  • Bladder dysfunction (urinary urgency/frequency) is a common non-motor disorder in Parkinson's disease (PD).
  • In contrast to motor disorders, bladder dysfunction is sometimes non-responsive to levodopa treatment.
  • The brain pathology causing the bladder dysfunction (appearance of overactivity) involves an altered dopamine basal ganglia-frontal circuit, which normally suppresses the micturition reflex.
  • The pathophysiology of the bladder dysfunction in PD differs from that in multiple system atrophy; therefore, it might aid in differential diagnosis.
  • Anticholinergic agents are used to treat bladder dysfunction in PD, although these drugs should be used with caution particularly in elderly patients who have cognitive decline.
  • [MeSH-major] Parkinson Disease / complications. Urinary Bladder Diseases / etiology
  • [MeSH-minor] Basal Ganglia / physiopathology. Cholinergic Antagonists / therapeutic use. Dopamine / physiology. Dopamine Agents / therapeutic use. Electromyography. Humans. Male. Transurethral Resection of Prostate / adverse effects. Urinary Bladder / physiopathology. Urination / physiology. Urination Disorders / etiology. Urination Disorders / physiopathology. Urodynamics

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • HSDB. structure - DOPAMINE.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 Elsevier Inc. All rights reserved.
  • (PMID = 22015601.001).
  • [ISSN] 1095-953X
  • [Journal-full-title] Neurobiology of disease
  • [ISO-abbreviation] Neurobiol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholinergic Antagonists; 0 / Dopamine Agents; VTD58H1Z2X / Dopamine
  •  go-up   go-down


22. |||||..... 50%  Hameed O, Humphrey PA: Pseudoneoplastic mimics of prostate and bladder carcinomas. Arch Pathol Lab Med; 2010 Mar;134(3):427-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoneoplastic mimics of prostate and bladder carcinomas.
  • CONTEXT: The differential diagnoses of prostatic carcinoma and bladder epithelial neoplasms include several histologic mimics that should be known to avoid misdiagnosis.
  • OBJECTIVE: To discuss pseudoneoplastic lesions of the prostate and bladder that could potentially be confused with prostatic carcinoma and bladder epithelial neoplasms, respectively, with specific focus on their distinguishing histopathologic features.
  • CONCLUSIONS: Pseudoneoplastic lesions in the prostate include those of prostatic epithelial origin, the most common being atrophy, adenosis (atypical adenomatous hyperplasia), basal cell hyperplasia, and crowded benign glands, as well as those of nonprostatic origin, such as seminal vesicle epithelium.
  • Such lesions often mimic lower-grade prostatic adenocarcinoma, whereas others, such as clear cell cribriform hyperplasia and granulomatous prostatitis, for example, are in the differential diagnosis of Gleason adenocarcinoma, Gleason grade 4 or 5.
  • Pseudoneoplastic lesions of the urinary bladder include lesions that could potentially be confused with urothelial carcinoma in situ, such as reactive urothelial atypia, and others, such as polypoid/papillary cystitis, where papillary urothelial neoplasms are the main differential diagnostic concern.
  • Diagnostic awareness of the salient histomorphologic and relevant immunohistochemical features of these prostatic and urinary bladder pseudoneoplasms is critical to avoid rendering false-positive diagnoses of malignancy.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Prostatic Diseases / diagnosis. Urinary Bladder Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Prostatic Neoplasms / classification. Prostatic Neoplasms / diagnosis. Urinary Bladder Neoplasms / classification. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20196670.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 83
  •  go-up   go-down


23. |||||..... 50%  Hironishi M, Ishimoto S, Sawanishi T, Miwa H, Kawachi I, Kondo T: [Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years]. Brain Nerve; 2012 Aug;64(8):951-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
  • The initial symptoms of NMO, including headache, high fever, retrobulbar optic neuritis, and neurogenic bladder, appeared at the age of 30.
  • Spinal MRI after frequent NMO attacks for 30 years revealed an extended spinal cord atrophy involving the lower cervical region and the entire thoracic region.
  • [MeSH-minor] Atrophy / pathology. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Myasthenia Gravis / pathology. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Devic Disease.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22868887.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aquaporin 4
  •  go-up   go-down


24. |||||..... 49%  VanderBrink BA, Stock JA, Hanna MK: Aesthetic aspects of reconstructive clitoroplasty in females with bladder exstrophy-epispadias complex. J Plast Reconstr Aesthet Surg; 2010 Dec;63(12):2141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aesthetic aspects of reconstructive clitoroplasty in females with bladder exstrophy-epispadias complex.
  • BACKGROUND: Genital anomalies in females born with classic bladder exstrophy-epispadias complex (EEC) include a bifid clitoris and anterior displacement of vagina.
  • METHODS: The study group had 26 female patients; three patients with isolated epispadias and 23 with bladder exstrophy.
  • Three patients had partial clitoral atrophy and in one patient the gap between clitoral bodies was widely separated and incapable of being joined.
  • [MeSH-major] Bladder Exstrophy / surgery. Epispadias / surgery. Genitalia, Female / surgery. Gynecologic Surgical Procedures / methods. Reconstructive Surgical Procedures / methods
  • [MeSH-minor] Atrophy. Child. Child, Preschool. Esthetics. Female. Humans. Infant. Infant, Newborn. Patient Satisfaction. Reoperation. Treatment Outcome

  • Genetic Alliance. consumer health - Epispadias.
  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20303329.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


25. |||||..... 49%  Lin YC, Chiu KH, Shiea J, Huang HW, Mok HK: Seasonal changes in atrophy-associated proteins of the sonic muscle in the big-snout croaker, Johnius macrorhynus (Pisces, Sciaenidae), identified by using a proteomic approach. Fish Physiol Biochem; 2011 Dec;37(4):977-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seasonal changes in atrophy-associated proteins of the sonic muscle in the big-snout croaker, Johnius macrorhynus (Pisces, Sciaenidae), identified by using a proteomic approach.
  • In most sciaenids, males possess sonic muscles and produce sound through the contraction of these muscles and amplification of the swim bladder.
  • The protein profiles of the sonic muscle, red muscle, and white muscle in the Johnius macrorhynus were shown by two-dimensional electrophoresis (2-DE) and were compared to reveal differential protein expressions.
  • Seasonal hypertrophy and atrophy of the sonic muscles related to the reproductive cycle were verified in male big-snout croaker.
  • [MeSH-minor] Animals. Atrophy. Electrophoresis, Gel, Two-Dimensional. Hypertrophy. Male. Muscle Contraction. Proteomics. Seasons

  • ResearchGate. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21553060.001).
  • [ISSN] 1573-5168
  • [Journal-full-title] Fish physiology and biochemistry
  • [ISO-abbreviation] Fish Physiol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Muscle Proteins
  •  go-up   go-down


26. |||||..... 49%  Tsunoyama K, Sakakibara R, Yamaguchi C, Uchiyama T, Yamamoto T, Yamanishi T, Takahashi O, Sugiyama M, Kishi M, Ogawa E: Pathogenesis of reduced or increased bladder sensation. Neurourol Urodyn; 2011 Mar;30(3):339-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of reduced or increased bladder sensation.
  • OBJECTIVE: Pathogenesis of reduced or increased bladder sensation is not well known.
  • Hence, we systematically investigated the frequency of reduced or increased bladder sensation in neurologic/mental diseases.
  • Data registries included a diagnosis, a lower urinary tract symptom questionnaire, a urodynamic study, and neurological examinations.
  • Reduced bladder sensation is defined as bladder volume at the first sensation >300 ml.
  • Increased bladder sensation is defined as bladder volume at the first sensation <100 ml.
  • RESULTS: Neuropathies are the most common cause of reduced bladder sensation (33.3-43.8% in diabetic neuropathy, etc.).
  • Less common is brain diseases (9.6% in multiple system atrophy, etc.).
  • In contrast, myelopathies are the most common cause of increased bladder sensation without DO (25.0-40.0% in spinal forms of systemic lupus erythematosus, Sjogren's syndrome, etc.).
  • Less common is brain/mental diseases (20.0% in psychogenic bladder dysfunction, 8.1% in Parkinson's disease, etc.).
  • CONCLUSION: The present study revealed that neuropathies are the most common cause of reduced bladder sensation in neurologic/mental diseases.
  • Increased bladder sensation without DO occurs mainly in peripheral and central sensory pathway lesions, as well as in basal ganglia lesions and psychogenic bladder dysfunction.
  • Reduced and increased bladder sensation should be a major treatment target for maximizing patients' quality of life.
  • [MeSH-major] Hypesthesia / etiology. Sensation. Urinary Bladder / innervation. Urinary Bladder Diseases / etiology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 Wiley-Liss, Inc.
  • (PMID = 21305587.001).
  • [ISSN] 1520-6777
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. |||||..... 49%  Barnes CS, Yan J, Wilmot GR: A negative electroretinogram (ERG) in a case of probable multiple system atrophy (MSA). Doc Ophthalmol; 2009 Jun;118(3):247-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A negative electroretinogram (ERG) in a case of probable multiple system atrophy (MSA).
  • The 65-year-old man had a 5-year history of ataxia, unsteady gait, orthostatic hypotension, and bladder and erectile dysfunction, with no family history of neurological or retinal disease.
  • Blood tests were negative for Leber's hereditary optic neuropathy, dominant optic atrophy, and for expansions in SCA genes including SCA-1.
  • The patient's prominent autonomic dysfunction differs from the previous cases, and meets the clinical criteria for probable multiple system atrophy (MSA).
  • This introduces another possible diagnosis in cases of negative ERGs with ataxia, and suggests that the visual system may be affected in MSA.
  • [MeSH-major] Electroretinography. Multiple System Atrophy / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Autonomic Nervous System Diseases / diagnosis. Color Vision. Diagnosis, Differential. Female. Fundus Oculi. Humans. Male. Middle Aged. Spinocerebellar Degenerations / diagnosis. Visual Fields

  • Genetic Alliance. consumer health - Multiple system atrophy.
  • Genetics Home Reference. consumer health - multiple system atrophy.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023607.001).
  • [ISSN] 1573-2622
  • [Journal-full-title] Documenta ophthalmologica. Advances in ophthalmology
  • [ISO-abbreviation] Doc Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


28. |||||..... 49%  Bodareva NV, Anichkov NM, Komiakov BK: [Adaptive changes in enteric explants instead of the urinary bladder]. Arkh Patol; 2011 Jan-Feb;73(1):27-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adaptive changes in enteric explants instead of the urinary bladder].
  • One hundred and twenty-two biopsy specimens of enteric explants (orthotopic urinary reservoirs (OUR)) placed instead of the neoplastic urinary bladder were studied in 94 patients.
  • (1) progressive atrophy and a reduction in enteric villae; brush-border enterocyte replacement by goblet cells secreting syalomucins with the appearance of the lining devoid of the brush border and secretion;.
  • [MeSH-major] Intestine, Small. Urinary Bladder / pathology. Urinary Bladder / surgery. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urologic Surgical Procedures

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21506337.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


29. |||||..... 48%  Tanidir Y, Ercan F, Tarcan T: Exogenous testosterone and estrogen affect bladder tissue contractility and histomorphology differently in rat ovariectomy model. J Sex Med; 2011 Jun;8(6):1626-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exogenous testosterone and estrogen affect bladder tissue contractility and histomorphology differently in rat ovariectomy model.
  • INTRODUCTION: Changes in sex hormone levels may play a role in the etiology of lower urinary tract dysfunction of aging women where the possible role of testosterone is overlooked.
  • AIM: To determine the effect of testosterone with/without estrogen replacement on histological and functional deterioration in ovariectomized rat bladder tissue.
  • Nine weeks after ovariectomy, bladder strips were harvested for isometric tension and histopathological studies.
  • MAIN OUTCOME MEASURES: To assess the effect of testosterone/estradiol on ovariectomized rat bladder tissue function and histomorphology.
  • RESULTS: OVX and VA groups showed statistically significant histological changes such as urothelial damage, inflammatory cell infiltration, increase in collagen fibers and muscular atrophy compared with the control group.
  • CONCLUSION: Either estradiol or testosterone replacement alone or in combination prevents significant alterations in bladder tissue histology following ovariectomy whereas both affect the bladder tissue contractility.
  • Thus, combination treatment appears to be the best method to restore both contractility and histomorphology of bladder tissue after ovariectomy.
  • [MeSH-major] Estradiol / pharmacology. Isometric Contraction / drug effects. Ovariectomy. Testosterone / analogs & derivatives. Urinary Bladder / anatomy & histology. Urinary Bladder / drug effects. Urodynamics / drug effects

  • HSDB. structure - ESTRADIOL.
  • HSDB. structure - TESTOSTERONE.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2011 International Society for Sexual Medicine.
  • (PMID = 21366882.001).
  • [ISSN] 1743-6109
  • [Journal-full-title] The journal of sexual medicine
  • [ISO-abbreviation] J Sex Med
  • [Language] eng
  • [Publication-type] In Vitro; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 5949-44-0 / testosterone undecanoate
  •  go-up   go-down


30. |||||..... 48%  Swaminath PV, Ragothaman M, Koshy S, Sarangmath N, Adhyam M, Subbakrishna DK, Mathias CJ, Muthane UB: Urogenital symptoms in Parkinson's disease and multiple system atrophy-Parkinsonism: at onset and later. J Assoc Physicians India; 2010 Feb;58:86-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urogenital symptoms in Parkinson's disease and multiple system atrophy-Parkinsonism: at onset and later.
  • An autonomic questionnaire was used to document urinary and genital symptoms.
  • Urinary symptoms occurred twice as frequently in MSA-P than in PD.
  • [MeSH-major] Multiple System Atrophy / complications. Parkinsonian Disorders / complications. Sexual Dysfunction, Physiological / etiology. Urinary Bladder Diseases / etiology. Urination Disorders / etiology
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prospective Studies. Urodynamics


31. |||||..... 48%  Yu Y, Shen Z, Zhou X, Chen S: Effects of steroid hormones on morphology and vascular endothelial growth factor expression in female bladder. Urology; 2009 Jun;73(6):1210-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of steroid hormones on morphology and vascular endothelial growth factor expression in female bladder.
  • OBJECTIVES: To investigate the roles of steroid hormones, including estrogen, progesterone, and testosterone, in the morphology and vascularization of the female bladder.
  • The total weight and thickness of the bladder were measured.
  • The expression of vascular endothelial growth factor (VEGF) in the bladder was evaluated by immmohistochemistry and Western blotting.
  • RESULTS: The ovariectomized rats had a thinner bladder wall compared with the sham group (0.97 +/- 0.11 mm vs 1.10 +/- 0.10 mm, P < .05) and widened spaces between the detrusor muscle fascicles with collagen deposit.
  • Estrogen reversed these changes, and testosterone increased the thickness of the bladder wall to 1.26 +/- 0.12 mm (P < .05).
  • CONCLUSIONS: Our findings suggest the importance of steroid hormones in maintaining the integrity of the bladder structure and regulating the expression of VEGF in the female urinary tract.
  • Both estrogen and androgen can reverse the bladder muscle atrophy induced by ovariectomy.
  • However, the decline in VEGF expression in the bladder cannot be fully recovered with either estrogen or androgen replacement.
  • [MeSH-major] Estradiol / analogs & derivatives. Progesterone / pharmacology. Testosterone Propionate / pharmacology. Urinary Bladder / metabolism. Urinary Bladder / pathology. Vascular Endothelial Growth Factor A / biosynthesis

  • HSDB. structure - ESTRADIOL.
  • HSDB. structure - PROGESTERONE.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19376567.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 1S4CJB5ZGN / estradiol 3-benzoate; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; WI93Z9138A / Testosterone Propionate
  •  go-up   go-down


32. |||||..... 48%  Pisarev SA: [Blood lymphocytes and mast cells of the detrusor as diagnostic markers of overactive urinary bladder and its immune inflammation]. Urologiia; 2009 May-Jun;(3):29-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Blood lymphocytes and mast cells of the detrusor as diagnostic markers of overactive urinary bladder and its immune inflammation].
  • To identify clinico-laboratory symptoms and pathogenetic factors of overactive bladder syndrome (OBS), we used cytochemical analysis of peripheral blood lymphocyte enzymes in 88 males and females aged 50-75 years with this syndrome (70 patients) and control (18 subjects).
  • Biopsy of the anterior wall of the bladder with examination of detrusor myocytes was made in 28 of 70 patients.
  • OBS patients were found to have reduced aerobic respiration in blood lymphocytes and detruzor cells, dystrophy and atrophy of myocytes, moderate interstitial cell infiltration of the detrusor in increasing number and activity of mast cells, T-lymphocytes (CD4, CD8) and macrophages (CD11).
  • We came to the conclusion that development and symptoms of OBS are caused by low energetic activity of the detrusor in line with dysfunction of the bladder mast cells and immunity factors.
  • This is important for diagnosis of OBS severity and choice of energotropic therapeutic measures.
  • [MeSH-major] Lymphocytes. Mast Cells. Muscle, Smooth / cytology. Urinary Bladder / immunology. Urinary Bladder, Overactive / diagnosis. Urinary Bladder, Overactive / immunology

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670813.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii͡a (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 1.1.- / Glycerolphosphate Dehydrogenase; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


33. |||||..... 48%  Radziszewski P, Baranowski W, Nowak-Markwitz E, Rechbeger T, Suzin J, Witek A, Expert Panel: [Expert panel recommendations on therapeutic and diagnostic management of urinary incontinence and overactive bladder in women]. Ginekol Pol; 2010 Oct;81(10):789-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expert panel recommendations on therapeutic and diagnostic management of urinary incontinence and overactive bladder in women].
  • The expert panel recommendations are issued in order to increase the number of patients with urinary incontinence and overactive bladder receiving appropriate care.
  • The initial management of stress urinary incontinence should include lifestyle interventions, and physiotherapy Use of pessaries is acceptable in women who are not fit or do not want surgical therapy Local estrogen therapy should only be used in women with urogenital atrophy Duloxetin is an option in the pharmacological therapy of stress incontinence, but it doesn't cure the disease.
  • The ineffectiveness of initial procedure should be indication to surgery Alphaadrenomimetic drugs are not recommended in the therapy of urinary incontinence.
  • The initial management of overactive bladder and urgency incontinence should include lifestyle interventions, however fluid restrictions (if fluid load is less than 3000 ml) are not recommended.
  • The cornerstone of overactive bladder and urgency incontinence therapy remains the treatment with anticholinergic drugs.
  • [MeSH-major] Urinary Bladder, Overactive / diagnosis. Urinary Bladder, Overactive / therapy. Urinary Incontinence / diagnosis. Urinary Incontinence / therapy. Women's Health


34. |||||..... 48%  Ludwig L, Seraphim D, Lorenzetti F, Bertolla RP, Ortiz V, Dambros M: Inhibitory activity of α-tocopherol on apoptosis in the rat bladder wall subjected to androgen deprivation. Neurourol Urodyn; 2011 Jan;30(1):194-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory activity of α-tocopherol on apoptosis in the rat bladder wall subjected to androgen deprivation.
  • Thus to add to this knowledge in this study we studied the potential inhibitory activity on oxidative stress and process apoptosis on bladder wall in male rats subjected to androgen deprivation.
  • A causal relationship between lower testosterone levels and apoptosis, as a component of castration-induced muscle atrophy, has been shown.
  • [MeSH-major] Antioxidants / pharmacology. Apoptosis / drug effects. Oxidative Stress / drug effects. Urinary Bladder / metabolism. alpha-Tocopherol / pharmacology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • HSDB. structure - PROSTAGLANDIN F2ALPHA.
  • HSDB. structure - TESTOSTERONE.
  • HSDB. structure - VITAMIN E.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Wiley-Liss, Inc.
  • (PMID = 20665547.001).
  • [ISSN] 1520-6777
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 27415-26-5 / 8-epi-prostaglandin F2alpha; 3XMK78S47O / Testosterone; B7IN85G1HY / Dinoprost; EC 3.4.22.- / Caspase 3; H4N855PNZ1 / alpha-Tocopherol
  •  go-up   go-down


35. |||||..... 48%  Diamond P, Hassonah S, Alarab M, Lovatsis D, Drutz HP: The prevalence of detrusor overactivity amongst patients with symptoms of overactive bladder: a retrospective cohort study. Int Urogynecol J; 2012 Nov;23(11):1577-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of detrusor overactivity amongst patients with symptoms of overactive bladder: a retrospective cohort study.
  • INTRODUCTION AND HYPOTHESIS: Overactive bladder (OAB) is a symptom-based condition consisting of urgency, with or without incontinence, usually with frequency and nocturia.
  • Urogenital atrophy and incomplete emptying were more common.
  • [MeSH-major] Muscle, Smooth / physiopathology. Urinary Bladder, Overactive / epidemiology. Urinary Bladder, Overactive / physiopathology

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int Urogynecol J. 2013 May;24(5):887-8 [23572086.001]
  • [CommentIn] Int Urogynecol J. 2013 May;24(5):885 [23572087.001]
  • (PMID = 22531957.001).
  • [ISSN] 1433-3023
  • [Journal-full-title] International urogynecology journal
  • [ISO-abbreviation] Int Urogynecol J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholinergic Antagonists
  •  go-up   go-down


36. |||||..... 48%  Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, van der Kwast TH, Fleshner NE, Jewett MA, Finelli A, Schulman C, Lotan Y, Shariat SF, Nortier J: Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. Eur Urol; 2011 Jun;59(6):1026-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer.
  • BACKGROUND: More than 25% of bladder cancer (BC) cases are still muscle-invasive at first diagnosis.
  • MEASUREMENTS: Patients were evaluated for presence of BC and tumor stage at diagnosis.
  • Among 43 patients who underwent screening cystoscopies (median follow-up: 94 mo), 22 were first diagnosed with non-muscle-invasive BC but none with muscle-invasive tumors and none died of BC.
  • [MeSH-major] Anti-Obesity Agents / adverse effects. Aristolochic Acids / adverse effects. Cystoscopy. Drugs, Chinese Herbal / adverse effects. Kidney Diseases / chemically induced. Mass Screening / methods. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Atrophy. Biopsy. Early Detection of Cancer. Female. Fibrosis. Humans. Male. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Risk Assessment. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 21458152.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Obesity Agents; 0 / Aristolochic Acids; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


37. |||||..... 47%  Comiter C, Phull HS: Angiotensin II type 1 (AT-1) receptor inhibition partially prevents the urodynamic and detrusor changes associated with bladder outlet obstruction: a mouse model. BJU Int; 2012 Jun;109(12):1841-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiotensin II type 1 (AT-1) receptor inhibition partially prevents the urodynamic and detrusor changes associated with bladder outlet obstruction: a mouse model.
  • Angiotensin II is the main effector peptide in the bladder local renin-angiotensin system.
  • This experiment demonstrates the role of this local renin-angiotensin system with respect to bladder outlet obstruction.
  • OBJECTIVE: • To determine if treatment with an angiotensin II type 1 (AT-1) receptor antagonist, losartan, can prevent the structural and functional changes that occur in a mouse model of bladder outlet obstruction (BOO).
  • Six mice served as unobstructed controls, and six unobstructed mice were given oral losartan (10 mg/kg/day) to determine the effect of angiotensin II inhibition on the normal bladder.
  • Bladder capacity (C), detrusor pressure during voiding (Pdet) and volume at first non-voiding contraction (NVC1) as a percentage of C were recorded after 6 weeks.
  • • Bladders were stained with haematoxylin and eosin for measurement of detrusor muscular thickness, and graded as 1 = atrophy (<100 µm thick), 2 = normal (100-200 µm thick), 3 = hypertrophy (>200 µm thick) compared with controls.
  • BOO mice manifested greater bladder weight (93.2 ± 11.7 mg vs 26.8 ± 2.40 mg, P < 0.01) and greater detrusor muscle thickness (median 3 vs 2, P= 0.02).
  • • Treatment with losartan mediated an insignificant reduction in mean bladder weight (68.1 ± 9.1 mg vs 93.2 ± 11.7 mg, P= 0.10), but a significant reduction in detrusor muscle thickness (median 2 vs 3, P= 0.02).
  • Losartan did not mediate any significant structural or functional changes in the unobstructed mouse bladder.
  • [MeSH-major] Angiotensin II Type 1 Receptor Blockers / pharmacology. Losartan / pharmacology. Muscle, Smooth / drug effects. Urinary Bladder Neck Obstruction / drug therapy. Urodynamics / drug effects

  • HSDB. structure - LOSARTAN POTASSIUM.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.
  • (PMID = 21939491.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; JMS50MPO89 / Losartan
  •  go-up   go-down


38. |||||..... 47%  Ali-El-Dein B, Ashamallah A: Vaginal repair of pouch-vaginal fistula after orthotopic bladder substitution in women. Urology; 2013 Jan;81(1):198-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginal repair of pouch-vaginal fistula after orthotopic bladder substitution in women.
  • OBJECTIVE: To report the diagnosis, technique, and treatment outcome of pouch-vaginal fistula (PVF) with particular stress on the vaginal repair.
  • Certain modifications were adopted after 100 patients to prevent chronic urinary retention and PVF.
  • Transabdominal repair was used in 2 patients(high, large, vaginal atrophy) and the other patients underwent a vaginal repair in nonopposing layers 3 to 6 months after cystectomy.
  • It is recommended in low, small fistula and if postmenopausal vaginal atrophy is absent.
  • [MeSH-major] Urinary Fistula / surgery. Urinary Reservoirs, Continent / adverse effects. Vagina / surgery. Vaginal Fistula / surgery

  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 Elsevier Inc. All rights reserved.
  • [CommentIn] Urology. 2013 Jan;81(1):202-3; author reply 203 [23206583.001]
  • (PMID = 23206581.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. |||||..... 46%  Mehnert U, Nehiba M: [Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology, and treatment options]. Urologe A; 2012 Feb;51(2):189-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology, and treatment options].
  • The lower urinary tract (LUT) is regulated by a complex neural network that is subject to supraspinal control.
  • Multiple sclerosis, Parkinson's disease, multiple system atrophy, and stroke are neurological disorders which quite frequently cause dysfunction of the LUT.
  • With respect to the pathophysiology of bladder dysfunction in CNS diseases there are various hypotheses regarding the individual disorders: disturbances of neural communication between the frontal cortex and pontine micturition center, between the pontine micturition center and the lumbosacral parts of the spinal cord, and between the basal ganglia, thalamus, and anterior cingulate gyrus appear to play a pivotal role in the development of bladder dysfunction.
  • Surgical methods include reconstructive continent or incontinent urinary diversion.When planning therapy the patient's current needs and neurological limitations as well as possible disease progression must be taken into consideration.
  • [MeSH-major] Central Nervous System Diseases / complications. Central Nervous System Diseases / physiopathology. Lower Urinary Tract Symptoms / etiology. Lower Urinary Tract Symptoms / physiopathology. Urinary Bladder, Neurogenic / etiology. Urinary Bladder, Neurogenic / physiopathology
  • [MeSH-minor] Brain / physiopathology. Cross-Sectional Studies. Electric Stimulation Therapy. Humans. Multiple Sclerosis / complications. Multiple Sclerosis / physiopathology. Multiple Sclerosis / therapy. Multiple System Atrophy / complications. Multiple System Atrophy / physiopathology. Multiple System Atrophy / therapy. Neural Pathways / physiopathology. Parkinson Disease / complications. Parkinson Disease / physiopathology. Parkinson Disease / therapy. Spinal Cord / physiopathology. Stroke / complications. Stroke / physiopathology. Stroke / therapy. Treatment Outcome. Urethra / innervation. Urinary Bladder / innervation. Urodynamics / physiology

  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22331072.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


40. |||||..... 46%  Fowler CJ, Dalton C, Panicker JN: Review of neurologic diseases for the urologist. Urol Clin North Am; 2010 Nov;37(4):517-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article reviews the neurologic conditions associated with a high prevalence of bladder dysfunction and about which significant advances in understanding have occurred in recent years.
  • The importance of the frontal lobes for bladder control has been confirmed through functional brain imaging, and recent findings in the elderly with incontinence suggest the problem may result from disconnection of important frontal areas caused by white matter disease.
  • The very different urologic profile of the two sometimes-confused conditions, multiple system atrophy and Parkinson's disease, is clarified.
  • [MeSH-major] Nervous System Diseases / complications. Urinary Bladder, Neurogenic / etiology
  • [MeSH-minor] Aging. Frontal Lobe / physiopathology. Multiple Sclerosis / complications. Multiple Sclerosis / drug therapy. Multiple System Atrophy / complications. Parkinson Disease / complications. Urinary Incontinence / etiology. Urology

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20955903.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


41. |||||..... 46%  Yamamoto T, Sakakibara R, Uchiyama T, Yamaguchi C, Nomura F, Ito T, Yanagisawa M, Yano M, Awa Y, Yamanishi T, Hattori T, Kuwabara S: Pelvic organ dysfunction is more prevalent and severe in MSA-P compared to Parkinson's disease. Neurourol Urodyn; 2011 Jan;30(1):102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: It is usually difficult to distinguish between idiopathic Parkinson's disease (PD) and parkinsonian-type multiple system atrophy (MSA-P) in the early stage.
  • However, it is important to make a careful early-stage diagnosis.
  • The questionnaire had sections focusing on bladder, bowel, and sexual function.
  • RESULTS: Compared with the PD group, the prevalence and severity of pelvic dysfunction in the MSA-P group was significantly higher for urinary urgency (MSA-P 76%, PD 58%, P<0.05), retardation in initiating urination (79%, 48%, P<0.05), prolongation in urination (79%, 72%, P<0.05), and constipation (58%, 31%, P<0.05).
  • The quality-of-life index among pelvic organ dysfunctions indicated that urinary and bowel function was significantly more impaired in the MSA-P group than in the PD group.
  • CONCLUSIONS: Urinary urgency, retardation in initiating urination, prolongation in urination, and constipation are more prevalent and severe in MSA-P compared to PD.
  • [MeSH-major] Constipation / etiology. Multiple System Atrophy / complications. Parkinson Disease / complications. Pelvis / physiopathology. Urinary Bladder Diseases / etiology
  • [MeSH-minor] Aged. Diagnosis, Differential. Early Diagnosis. Female. Humans. Male. Middle Aged. Prevalence. Questionnaires. Severity of Illness Index


42. |||||..... 46%  de Kort LM, Bower WF, Swithinbank LV, Marschall-Kehrel D, de Jong TP, Bauer SB: The management of adolescents with neurogenic urinary tract and bowel dysfunction. Neurourol Urodyn; 2012 Sep;31(7):1170-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of adolescents with neurogenic urinary tract and bowel dysfunction.
  • Most children with neurogenic bladder dysfunction arrive into adolescence with reasonably managed lower urinary tract function only to experience bladder and kidney function deterioration after puberty.
  • The aim of this article is to identify issues that contribute to adverse changes in bladder and renal function during adolescence and to highlight strategies to preserve urinary tract integrity, social continence, patient autonomy, and independence.
  • Surveillance of bladder function requires patient attendance at review appointments and compliance with treatment plans.
  • Annual surveillance of adolescent neurogenic bladder patients facilitates early identification of risk factors for urinary tract deterioration.
  • Investigations include renal and bladder ultrasonography, urodynamic study when indicated, substantiated by videocystometry when anatomical status dictates.
  • Serum creatinine should be measured and renal scintigraphy performed when upper urinary tract dilation, renal scarring, or atrophy are suspected.
  • Optimal management of adolescents with neurologic disease of the urinary tract included strategies to reduce elevated detrusor pressure, maintain bladder compliance, and maximize dryness.
  • Caring for the patient as a whole requires discussion of sexuality, fertility status, and behaviors that increase the risk of progressive urinary tract damage.
  • [MeSH-major] Adolescent Behavior. Neurogenic Bowel / therapy. Patient Compliance. Urinary Bladder / physiopathology. Urinary Bladder, Neurogenic / therapy

  • MedlinePlus Health Information. consumer health - Child Behavior Disorders.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 Wiley Periodicals, Inc.
  • (PMID = 22460386.001).
  • [ISSN] 1520-6777
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biological Markers; AYI8EX34EU / Creatinine
  •  go-up   go-down


43. |||||..... 46%  Soria-Fernández GR, Jungfermann-Guzman JR, Lomelín-Ramos JP, Jaspersen-Gastelum J, Rosas-Nava JE: [Large benign prostatic hiperplasia]. Cir Cir; 2012 Nov-Dec;80(6):543-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hiperplasia prostática benigna de gran volumen.
  • The association between prostate growth and urinary obstruction in older adults is well documented.
  • CLINICAL CASE: we report the case of an 81-year-old who had significant symptoms relating to storage and bladder emptying, with no significant elevation of prostate specific antigen.
  • [MeSH-minor] Aged, 80 and over. Atrophy. Humans. Hyperplasia. Male. Organ Size. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatectomy / methods. Prostatitis / complications. Urinary Bladder Neck Obstruction / etiology. Urinary Bladder Neck Obstruction / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23336149.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugia y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


44. |||||..... 46%  Sakakibara R, Uchiyama T, Yamanishi T, Kishi M: Sphincter EMG as a diagnostic tool in autonomic disorders. Clin Auton Res; 2009 Feb;19(1):20-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple system atrophy (MSA) is a neurodegenerative disease presenting with a combination of parkinsonian, cerebellar, and autonomic (including cardiovascular, urinary, and anorectal) dysfunction.
  • [MeSH-major] Anal Canal / physiology. Autonomic Nervous System Diseases / diagnosis. Electromyography. Urinary Tract Physiological Phenomena
  • [MeSH-minor] Diagnosis, Differential. Humans. Multiple System Atrophy / complications. Multiple System Atrophy / diagnosis. Parkinson Disease / complications. Parkinson Disease / diagnosis. Urinary Bladder, Neurogenic / etiology

  • MedlinePlus Health Information. consumer health - Autonomic Nervous System Disorders.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18780143.001).
  • [ISSN] 1619-1560
  • [Journal-full-title] Clinical autonomic research : official journal of the Clinical Autonomic Research Society
  • [ISO-abbreviation] Clin. Auton. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 82
  •  go-up   go-down


45. |||||..... 46%  Vigen RA, Arum CJ, Viset T, Chen D, Zhao CM: Experimental gastrocystoplasty in rats: risk of developing ECLoma. J Pediatr Urol; 2012 Apr;8(2):209-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue specimens of bladder and stomach were analyzed by means of pathology and immunohistochemistry.
  • RESULTS: Atrophy of gastric glands in the augmented bladders was found after gastrocystoplasty with either 10% or 90% fundectomy.
  • Gastrocystoplasty with 90% fundectomy resulted in hyperplasia of the oxyntic mucosa, enterochromaffin-like (ECL) cell hyperplasia and ECLoma in the remnant stomach, and atrophy of the oxyntic mucosa and ECLoma in the gastric segment of the bladder.
  • CONCLUSIONS: ECLoma could develop in the gastric segment of the bladder after gastrocystoplasty, particularly in the setting of hypergastrinemia.
  • The tumorigenesis of ECLoma seems to follow the same pathological pathway regardless of whether the oxyntic mucosa is located in the stomach or the bladder.
  • [MeSH-major] Carcinoid Tumor / pathology. Enterochromaffin-like Cells / pathology. Gastric Fundus / surgery. Gastroplasty / adverse effects. Stomach Neoplasms / pathology. Urinary Bladder / surgery. Urologic Surgical Procedures / adverse effects

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 21324420.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


46. |||||..... 46%  Brimo F, Epstein JI: Selected common diagnostic problems in urologic pathology: perspectives from a large consult service in genitourinary pathology. Arch Pathol Lab Med; 2012 Apr;136(4):360-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To review 3 common differential diagnoses encountered in a large consultation service in genitourinary pathology, including partial atrophy versus prostatic acinar adenocarcinoma, oncocytoma versus chromophobe renal cell carcinoma, and urothelial carcinoma in situ versus normal urothelium and reactive atypia.
  • CONCLUSIONS: Careful morphologic assessment and awareness of diagnostic pitfalls are fundamental in reaching a definitive diagnosis in most cases.
  • [MeSH-minor] Atrophy / pathology. Diagnosis, Differential. Humans. Kidney Neoplasms / pathology. Male. Prostate / pathology. Prostatic Neoplasms / pathology. Urinary Bladder / pathology. Urologic Neoplasms / pathology. Urothelium / pathology

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22458899.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Markers, Biological
  •  go-up   go-down


47. |||||..... 46%  Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S: Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet; 2012 Feb;285(2):397-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To assess the effects of the combination of pelvic floor rehabilitation and intravaginal estriol administration on stress urinary incontinence (SUI), urogenital atrophy and recurrent urinary tract infections in postmenopausal women.
  • RESULTS: After therapy, the symptoms and signs of urogenital atrophy significantly improved in both groups.
  • [MeSH-minor] Administration, Intravaginal. Analysis of Variance. Atrophy / drug therapy. Atrophy / physiopathology. Atrophy / rehabilitation. Dyspareunia / drug therapy. Dyspareunia / physiopathology. Dyspareunia / rehabilitation. Electric Stimulation Therapy. Female. Humans. Middle Aged. Postmenopause. Pressure. Urethra / physiopathology. Urinary Bladder / physiopathology. Urinary Incontinence, Stress / drug therapy. Urinary Incontinence, Stress / physiopathology. Urinary Incontinence, Stress / rehabilitation. Urinary Tract Infections / drug therapy. Urinary Tract Infections / physiopathology. Urinary Tract Infections / rehabilitation. Vagina / pathology. Vagina / physiopathology

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • HSDB. structure - ESTRIOL.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21706345.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] FB33469R8E / Estriol
  •  go-up   go-down


48. |||||..... 46%  Tan A, Unluoglu S, Bayol U, Emil Sayhan S, Altinel D: Ureteritis cystica presenting with atrophic kidney: report of a case. ScientificWorldJournal; 2010;10:1535-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ureteritis cystica is a rare proliferative condition that is found predominantly in the bladder, renal pelvis, and upper ureter.
  • In conclusion, ureteritis cystica is a benign and indolent lesion that needs to be kept in mind among the causes of renal atrophy.
  • [MeSH-major] Cysts / diagnosis. Kidney / pathology. Ureteral Diseases / diagnosis
  • [MeSH-minor] Aged. Atrophy / complications. Atrophy / diagnosis. Chronic Disease. Diagnosis, Differential. Female. Humans. Pyelonephritis / complications. Pyelonephritis / diagnosis

  • MedlinePlus Health Information. consumer health - Ureteral Disorders.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694450.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. |||||..... 46%  Woo LL, Hijaz A, Pan HQ, Kuang M, Rackley RR, Damaser MS: Simulated childbirth injuries in an inbred rat strain. Neurourol Urodyn; 2009;28(4):356-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urethral histology demonstrated marked disruption and atrophy of smooth and striated muscle in VD rats compared to shams and controls.
  • SDF-1 was significantly decreased in the urethra and vagina immediately after VD and in the bladder 24 hr after VD.
  • [MeSH-minor] Animals. Atrophy. Chemokine CCL7 / biosynthesis. Chemokine CCL7 / genetics. Chemokine CXCL12 / biosynthesis. Chemokine CXCL12 / genetics. Chemokines / biosynthesis. Female. Humans. Pregnancy. Rats. Rats, Inbred Lew. Rectum / injuries. Rectum / pathology. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation / physiology. Urinary Bladder / injuries. Urinary Bladder / pathology. Urinary Catheterization. Urodynamics / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Eur Urol. 2008 Jan;53(1):169-75 [17683852.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2179-86 [17604800.001]
  • [Cites] Neurourol Urodyn. 2008;27(6):553-8 [18551566.001]
  • [Cites] World J Urol. 2008 Aug;26(4):327-32 [18470515.001]
  • [Cites] Neurourol Urodyn. 2000;19(1):53-69 [10602248.001]
  • [Cites] J Urol. 2001 Jul;166(1):311-7 [11435892.001]
  • [Cites] BJU Int. 2002 Sep;90(4):403-7 [12175397.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):900-7 [12621134.001]
  • [Cites] J Urol. 2003 Sep;170(3):1027-31 [12913764.001]
  • [Cites] Urology. 2003 Nov;62(5):958-63 [14624934.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Jan;63(1):84-96 [14748564.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2004 Feb;44(1):19-23 [15089863.001]
  • [Cites] Int J Gynaecol Obstet. 2004 Jul;86 Suppl 1:S6-16 [15302563.001]
  • [Cites] Int J Cardiol. 2004 Jun;95 Suppl 1:S23-5 [15336840.001]
  • [Cites] J Exp Anim Sci. 1993 Sep;35(5-6):210-20 [8218436.001]
  • [Cites] Microsurgery. 1995;16(11):765-7 [9148107.001]
  • [Cites] Urology. 1998 Jul;52(1):143-51 [9671889.001]
  • [Cites] J Appl Physiol (1985). 2005 May;98(5):1884-90 [15591288.001]
  • [Cites] Trends Cardiovasc Med. 2005 Feb;15(2):57-63 [15885571.001]
  • [Cites] J Urol. 2006 Feb;175(2):601-4 [16407004.001]
  • [Cites] Lab Anim. 2006 Jan;40(1):1-8 [16460584.001]
  • [Cites] Spine J. 2006 Mar-Apr;6(2):113-9 [16517380.001]
  • [Cites] Biol Psychiatry. 2006 Jun 15;59(12):1208-18 [16458266.001]
  • [Cites] Obstet Gynecol. 2006 Oct;108(4):873-8 [17012448.001]
  • [Cites] Stem Cells. 2007 Jan;25(1):245-51 [17053210.001]
  • [Cites] J Urol. 2007 Apr;177(4):1568-72 [17382780.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Apr;292(4):R1738-44 [17204590.001]
  • [Cites] Anat Rec (Hoboken). 2007 Feb;290(2):145-54 [17441207.001]
  • [Cites] J Urol. 2008 Aug;180(2):753-9 [18554634.001]
  • (PMID = 18973147.001).
  • [ISSN] 1520-6777
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD038679; United States / NICHD NIH HHS / HD / R01 HD038679; United States / NICHD NIH HHS / HD / R01 HD038679-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ccl7 protein, rat; 0 / Chemokine CCL7; 0 / Chemokine CXCL12; 0 / Chemokines
  • [Other-IDs] NLM/ NIHMS65763; NLM/ PMC2668733
  •  go-up   go-down


50. |||||..... 46%  Woo GH, Jho YS, Bak EJ: Canine distemper virus infection in fennec fox (Vulpes zerda). J Vet Med Sci; 2010 Aug;72(8):1075-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologically, there were lymphohistiocytic meningoencephalitis with malacia, mild interstitial pneumonia, lymphoid depletion of lymphoid tissues and organs, and intestinal villous atrophy with intralesional coccidia.
  • There were many intracytoplasmic and/or intranuclear inclusion bodies in the epithelial cells of the medullary velum, lungs, liver, kidneys, trachea, pancreas, stomach, gall bladder, urinary bladder, and ureters, and in macrophages of malacia foci and lymphocytes and macrophages of lymphoid organs.
  • [MeSH-major] Distemper / diagnosis. Distemper Virus, Canine / pathogenicity
  • [MeSH-minor] Animals. Atrophy. DNA Primers. Dehydration / pathology. Dehydration / veterinary. Dehydration / virology. Dogs. Emaciation / pathology. Emaciation / veterinary. Emaciation / virology. Eye Diseases / pathology. Eye Diseases / veterinary. Eye Diseases / virology. Female. Foxes. Genome, Viral. Lymphoid Tissue / pathology. Lymphoid Tissue / virology. Male. Reverse Transcriptase Polymerase Chain Reaction. Sudan

  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20299771.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science / the Japanese Society of Veterinary Science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


top


2. Definitions


3. Related RMF webpages


terms of use | advertising programs | contact us
© 2014 RecentMedicalFindings


Connect with the


RMF


audience;




Post your ad here!